RECRUITING

High Dose Omeprazole in Patients With Pancreatic Cancer

Talk to us

Conditions

Exocrine Pancreatic Cancerpancreatic canceromeprazole

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to test the safety of high dose omeprazole and see what effects that it has on patients with exocrine pancreatic cancer.

Official Title

A Phase 0 Study of High Dose Omeprazole in Patients With Pancreatic Cancer Planning to Undergo Surgical Therapy for Evaluating Changes of Biomarkers

Quick Facts

Study Start:2021-09-07
Study Completion:2026-06
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04930991

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 99 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Newly diagnosed exocrine pancreatic cancer with pathology confirmed as adenocarcinoma
  2. * Patient is a candidate for surgical resection of pancreatic cancer
  3. * ≥ 18 years old at the time of informed consent
  4. * ECOG Performance Status 0-2
  5. * Patients with or without neoadjuvant chemotherapy will be eligible
  6. * Ability to provide written informed consent and HIPAA authorization
  7. * Women of childbearing potential definition must have a negative pregnancy test within 14 days of registration. All women (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) are considered to have childbearing potential unless they meet one of the following criteria:
  8. * Prior hysterectomy or bilateral oophorectomy;
  9. * Has not had menses at any time in the preceding 24 consecutive months
  10. * Adequate organ function for surgical therapy
  1. * Patients with pancreatic malignant tumor histologically confirmed as neuroendocrine or any other type of malignancies
  2. * Positive pregnancy test, pregnant, or breastfeeding
  3. * Known hypersensitivity to any component of the formulation or substituted benzimidazoles
  4. * Any other clinically significant laboratory abnormality that would compromise patient safety or the outcome of the study
  5. * Any clinically significant and/or uncontrolled cardiac-related abnormality that would compromise patient safety or the outcome of the study
  6. * Medical condition that might affect the absorption of study medications in the opinion of the investigator.

Contacts and Locations

Study Contact

SCC IIT Office
CONTACT
405-271-8777
SCC-IIT-Office@ouhsc.edu
Ingrid Block
CONTACT
405-271-8777

Principal Investigator

Ajay Jain, MD
PRINCIPAL_INVESTIGATOR
University of Oklahoma

Study Locations (Sites)

Stephenson Cancer Center
Oklahoma City, Oklahoma, 73104
United States

Collaborators and Investigators

Sponsor: University of Oklahoma

  • Ajay Jain, MD, PRINCIPAL_INVESTIGATOR, University of Oklahoma

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-09-07
Study Completion Date2026-06

Study Record Updates

Study Start Date2021-09-07
Study Completion Date2026-06

Terms related to this study

Keywords Provided by Researchers

  • pancreatic cancer
  • omeprazole

Additional Relevant MeSH Terms

  • Exocrine Pancreatic Cancer